http://www.clipsyndicate.com/rss/feed/2455 http://player.clipsyndicate.com/view/2455/651971 <table border='0' cellpadding='0' cellspacing='0'><tr valign='top'><td><a href='http://www.clipsyndicate.com/video/playlist/2455/651971/?cpt=8&wpid=1074'><img src='http://video-static.clipsyndicate.com/cs-video/vol2/2008/7/24/58/351/27bad5f4-063c-4965-a9c1-713e2b101aa4_120x90.jpg' border='0' /></a></td><td style='padding:5px;'>Interview with CEO John Lechleiter</td></tr></table> http://www.clipsyndicate.com/video/playlist/2455/651971/?cpt=8&wpid=1074 Thu, 24 Jul 2008 12:14:00 +0000 Spotlight: Eli Lilly Interview with CEO John Lechleiter http://www.clipsyndicate.com/video/playlist/2455/651971/?cpt=8&wpid=1074 Bloomberg-Clip there were some questions about your forecast. you want to clarify that your guidance is still the same for this year. > our full year, dense, which we gave at the beginning of the year of $3.85-$4 per share remains in tact. that is after taking into account significant items, such as the ones we hauled out this period. that is the range that oil be tracked by most of the analyst. that is still our guidance and we're on track. to meet its >> the biggest question concerning your company, and part of the reason your stock is down 14% this out on a stack of paper, it would have been as tall as the empire state building. this was quite a complex application. the fda tells us they need more time. they chose to take three months. we are pleased about that. the new action date is september 26. >> there are some expectations -- when the fda does approve it, could they approve it with limited uses? and if they would, how does it impact your strategy for that benefit from the full range of therapy that we believe this drug can offer. >> i also want to talk about your top-selling drug, zyprexa, which will be losing patent protection. a competing drug is coming -- is going generic, as well. do you expect that to affect sales? >> it is available in generic. keep in mind, we will also have a much greater share voice in the marketplace since the brand will no longer be actively promoted. we're doing several things to ensure that we maintain a strong reduces the cost associated with hospitalization by keeping people out of the hospital. we know that many people being treated for schizophrenia cycle through different drugs. even with the availability of a generic drug, we are sure that zyprexa will get its fair share of use. >> when it does come off patent protection, do you expect sales of some of the other drugs that did well this quarter like cymbalta, to be a will to make up the difference? >> cymbalta, cialas -- their products growing at strong, double-digit rates. that growth trajectory will continue through the 2011-2012 period. development, and seven so far this year that are entering clinical testing. we're focused on moving the pipeline forward. >> i spoke with the ceo of pfizer yesterday. you recently partnered with merck and pfizer developing drugs. is that the wave of the future? these big companies will have to get together in order to bring drugs to the market? >> all of us will have to find a fundamentally new ways to operate this business. the announcement that he refers to is a pretty competitive collaboration that we hope will result in new tools and new technology that each of the partner companies can then take and use to speed up their own drug discovery process these. <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=651971&cpt=8&wpid=1074"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=651971&cpt=8&wpid=1074" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> NYSE:LLY Legal,Bloomberg Business News,Business http://player.clipsyndicate.com/view/2455/649334 <table border='0' cellpadding='0' cellspacing='0'><tr valign='top'><td><a href='http://www.clipsyndicate.com/video/playlist/2455/649334/?cpt=8&wpid=1074'><img src='http://video-static.clipsyndicate.com/cs-video/vol2/2008/7/22/58/351/1f8ac8aa-bb6e-4cc4-ae39-00c90d49a5c4_120x90.jpg' border='0' /></a></td><td style='padding:5px;'>Schering-Plough, Merck's Vyortin fails to cut risk of heart valve diseases; Eisai wins appeal ruling to block generic Aciphex; Analysis by GV Pasad, Dr. Reddy's Laboratories Vice Chairman & CEO </td></tr></table> http://www.clipsyndicate.com/video/playlist/2455/649334/?cpt=8&wpid=1074 Tue, 22 Jul 2008 04:41:00 +0000 US Drugmakers Tumble; Insight, Outlook For Pharmaceutical Sector Schering-Plough, Merck's Vyortin fails to cut risk of heart valve diseases; Eisai wins appeal ruling to block generic Aciphex; Analysis by GV Pasad, Dr. Reddy's Laboratories Vice Chairman & CEO http://www.clipsyndicate.com/video/playlist/2455/649334/?cpt=8&wpid=1074 Bloomberg-Clip one cholesterol drug failed to study everything -- they are down by 11%, merck is down by 6%. this was connected to a higher rate of cancer. the revenue from these companies -- they are looking at a joint venture. there is a u.s. court ruling blocking the drug -- the court of appeals is forcing the japanese companies for taking these challenges. drugs -- this will expire in may of 2013. they generated $1.6 billion in global sales. a very good day, thank you for joing us. what would you do here right now? >> we have not finalized a strategy just yet. we are looking at the weaknesses -- this is a non infringement -- this is part of the business -- we are trying to get affordable medicine. >> is this going to be lost -- what do you believe that there will be an appeal. >> we have not made up our mind -- >> is this going to be affecting your profit outlook? >> we do not usually involve these. >> this was in line with analysts' estimates. these sales actually rose -- the question is, can you translate this into more profit? >> i believe that i am confident that we can. this will normalize what will happen in the coming quarter. we are launching this -- and we may see increased profitability. >> what kind of increased profits are you looking at right now? >> we are looking at the volatility right now. we will be increasing the profit in the long term. >> the u.s. sales rose 53%. do you have any other major market movements that you will see to keep the sales growing. >> of parts from germany and the > what about the weakness of the indian rupee against the dollar? what are you doing, are you hedging against the indian rupee? >> we have a little bit more exposure -- and we have a lot of this based on the imports, one- third of these we have left open. > thank you very much for joing us today. <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=649334&cpt=8&wpid=1074"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=649334&cpt=8&wpid=1074" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> NYSE:MRK, NYSE:SGP, TYO:4523, BOM:500124 News,Business,Bloomberg Business News,Pharma http://player.clipsyndicate.com/view/2455/648895 <table border='0' cellpadding='0' cellspacing='0'><tr valign='top'><td><a href='http://www.clipsyndicate.com/video/playlist/2455/648895/?cpt=8&wpid=1074'><img src='http://video-static.clipsyndicate.com/cs-video/vol2/2008/7/21/58/351/11e6a2f8-05cf-4ba4-b0b4-4d9743f6ebe9_120x90.jpg' border='0' /></a></td><td style='padding:5px;'>Analysis and Discussion with Joel Sendek of Lazard Capital Management</td></tr></table> http://www.clipsyndicate.com/video/playlist/2455/648895/?cpt=8&wpid=1074 Mon, 21 Jul 2008 19:31:00 +0000 M&A Spotlight: Roche to Buy Rest of Genentech for $43.7 Billion Analysis and Discussion with Joel Sendek of Lazard Capital Management http://www.clipsyndicate.com/video/playlist/2455/648895/?cpt=8&wpid=1074 Bloomberg-Clip gentech shares are gaing more than 11% today after roche offer to buy the rest of their shares for $43.7 billion, $89 a share. our next guest expects it genentech to refuse the bid. he is an analyst at lazard capital market and has a buy rating on gentech. thank you for coming on the show. first of all, why does roche have to bite? they only -- they already own 56 they already own 56% of the company. > we were hoping genentech would stay dependent. but it is trading such an attractive asset that it is easy not to make a bid. what are you expecting to play out here? obviously, investors think the shares will go for closer to $100. do think roche comes out and raises the bid? >> they will not do that immediately. they will have to go through a process. what is -- what will happen first is that there is the board of directors of genentech that will either accept or reject the bid. on the basis of that, they will go to the next step. our estimate is we think there's >> i am wondering about the timing of the deal. it does not look like they are at a weak point considering or their shares are trading. what is roche come in here and do it now? > there is a major catalyst coming up which is a steady for the major drug -- a steady about the major drug coming out. it could be what they want to do is get a bid in before the data comes out if they have insight that it will be positive. if they do it after that data, it is possible -- positive, they will get a higher price. >> what if they fail? what is the other option? they have the cash to do something. >> yes, they have cash. they have a pipeline that is not it remains to be seen whether genentech's view is on this. on the basis of covering the stock for 10 years so, my assumption is that genentech would prefer, even with this premium, to retake the economy. >> what if they do not get it? >> the gentech culture is a unique one. it is different from pharma and biotech. when they are not independent, yet to expect some attrition as far as the key people that have driven the pipeline over the 30 years the company has been in existence. >> that would make the deal even more expensive for roche. even if they buy it, they will have to convince scientists and consolidate all of roche's u.s. pharmaceutical business under the genentech and move it from new jersey over to south san francisco which is a considerable shift on the part of roche in an attempt to get this deal done. >> may be a nice move for those people working on the east coast to want a little more fun and sun. thank you so much for joing us. talking about the roche offer for genentech. <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=648895&cpt=8&wpid=1074"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=648895&cpt=8&wpid=1074" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> VTX:ROG, NYSE:DNA Business,Health,Law & Legal Issues,News,Personal Finance,Science & Technology,Shopping & Commerce http://player.clipsyndicate.com/view/2455/647253 <table border='0' cellpadding='0' cellspacing='0'><tr valign='top'><td><a href='http://www.clipsyndicate.com/video/playlist/2455/647253/?cpt=8&wpid=1074'><img src='http://video-static.clipsyndicate.com/cs-video/vol2/2008/7/18/58/351/caad32be-a5f0-4d48-9b7f-5134537b598f_120x90.jpg' border='0' /></a></td><td style='padding:5px;'>Joint Interview with Teva CEO Shlomo Yanai and Barr CEO Bruce Downey</td></tr></table> http://www.clipsyndicate.com/video/playlist/2455/647253/?cpt=8&wpid=1074 Fri, 18 Jul 2008 17:38:00 +0000 Inside Look: Teva Buying Barr (Part 1) Joint Interview with Teva CEO Shlomo Yanai and Barr CEO Bruce Downey http://www.clipsyndicate.com/video/playlist/2455/647253/?cpt=8&wpid=1074 Bloomberg-Clip the world's biggest maker of generic drugs, teva pharmaceuticals, agreed today to purchase barr pharmaceuticals, priced at $7.5 billion. joing us, both c.e.o.'s and the studio. welcome, gentlemen. glad to have you. it is unusual to have you acquire a stock on the day and acquisition is announced. is wall street happy with the premium that you paid? do you think the cash and stock combination made sense to investors? >> i think investors see this acquisition, and i think it is also a very compelling economically. > standard and poor's reaffirmed its aaa + rating on the company today. they say if you do in fact have your debt remaining more than a year, maybe they will revisit that rating. is that something of great concern or not? >> i think we have the cash flow and we're smart about it. within the fourth quarter of closing, we are ok. >> you said the timing was right of the purchase. why now? >> i think the strategic fit was very compelling, more so than in the past. this was the 12th serious attempt to acquire barr pharmaceuticals since i've been here, and none of the other 11 have seemed bright. this one was a strategic fit, particularly where we are in the business. generics are coming into the fore, the complementary nature of the eastern europe business, the u.s. business, or brand business fits with theirs. it was a compelling story, and i think that is what wall street is responding to. >> it is the geography counting more or the product lines? >> i think all of the factors. the real key to the reaction and teva's share price, it is widely recognized we have the two strongest companies in the industry and the combination creates separation between teva and the rest of the pack. i think people recognize that. >> you have a lot of competition in this generic field. >> that is true, but we believe that we can grow the business and get stronger and it is part of what we should do in this environment. >> we discussed this morning both the synergies that we expect from this transaction, but we also mentioned there is a big opportunity for us. teva has a growth strategy aimed to double the business. >> by 2012? > by 2012, 20/20 vision as we call it. we aim to double down on the product portfolios, getting the products, knowing how people will get that. <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=647253&cpt=8&wpid=1074"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=647253&cpt=8&wpid=1074" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> NASDAQ:TEVA, NYSE:BRL Business,Health,Law & Legal Issues,News,Personal Finance,Science & Technology,Shopping & Commerce http://player.clipsyndicate.com/view/2455/579578 <table border='0' cellpadding='0' cellspacing='0'><tr valign='top'><td><a href='http://www.clipsyndicate.com/video/playlist/2455/579578/?cpt=8&wpid=1074'><img src='http://video-static.clipsyndicate.com/cs-video/vol2/2008/4/29/58/351/0016032c-d77c-4b3d-9160-8248dfdb0dcb_120x90.jpg' border='0' /></a></td><td style='padding:5px;'>Merck Plans to Submit More Data to FDA to Prove Effectiveness of Drug</td></tr></table> http://www.clipsyndicate.com/video/playlist/2455/579578/?cpt=8&wpid=1074 Tue, 29 Apr 2008 12:50:00 +0000 Merck's Cholesterol Pill Fails to Win U.S. Approval Merck Plans to Submit More Data to FDA to Prove Effectiveness of Drug http://www.clipsyndicate.com/video/playlist/2455/579578/?cpt=8&wpid=1074 Bloomberg-Clip merck' holesterol pell has failed in approval fda egulators and hat causing the tock to all this morning. s less han one week after ecommendations or arketing rom the uropean union. he company plans o back to da to how he effectiveness he drug. da ays hat hey need to do more safety tests. bear stearns nalyst ays the holesterol drug ould ave 600 million in ales f approved. <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=579578&cpt=8&wpid=1074"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=579578&cpt=8&wpid=1074" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> NYSE:BSC, NYSE:MER Business,Health http://player.clipsyndicate.com/view/2455/577027 <table border='0' cellpadding='0' cellspacing='0'><tr valign='top'><td><a href='http://www.clipsyndicate.com/video/playlist/2455/577027/?cpt=8&wpid=1074'><img src='http://video-static.clipsyndicate.com/cs-video/vol2/2008/4/25/125/443/2b8fbc58-6645-4b0c-b66e-96ae781a443b_120x90.jpg' border='0' /></a></td><td style='padding:5px;'>Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX - News) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE - News), today announced that the U.S. Food and Drug Administration (FDA) has approved RELISTOR™ (methylnaltrexone bromide) subcutaneous injection for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient.</td></tr></table> http://www.clipsyndicate.com/video/playlist/2455/577027/?cpt=8&wpid=1074 Fri, 25 Apr 2008 13:27:48 +0000 Progenics and Wyeth Announce FDA Has Approved RELISTOR Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX - News) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE - News), today announced that the U.S. Food and Drug Administration (FDA) has approved RELISTOR™ (methylnaltrexone bromide) subcutaneous injection for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. http://www.clipsyndicate.com/video/playlist/2455/577027/?cpt=8&wpid=1074 News Broadcast Network <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=577027&cpt=8&wpid=1074"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=577027&cpt=8&wpid=1074" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> Health http://player.clipsyndicate.com/view/2455/574141 <table border='0' cellpadding='0' cellspacing='0'><tr valign='top'><td><a href='http://www.clipsyndicate.com/video/playlist/2455/574141/?cpt=8&wpid=1074'><img src='http://video-static.clipsyndicate.com/cs-video/vol2/2008/4/22/4/3/731f705b-3e7a-4c62-b64d-4a74646b0ce7_120x90.jpg' border='0' /></a></td><td style='padding:5px;'>House members chastised the Food and Drug Administration on Tuesday for not stepping up inspections of foreign drug manufacturers in the wake of a litany of problem with the blood thinner heparin and other products. (April 22)</td></tr></table> http://www.clipsyndicate.com/video/playlist/2455/574141/?cpt=8&wpid=1074 Tue, 22 Apr 2008 18:01:34 +0000 FDA Chief Questioned by Congress About Heparin House members chastised the Food and Drug Administration on Tuesday for not stepping up inspections of foreign drug manufacturers in the wake of a litany of problem with the blood thinner heparin and other products. (April 22) http://www.clipsyndicate.com/video/playlist/2455/574141/?cpt=8&wpid=1074 Associated Press <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=574141&cpt=8&wpid=1074"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=574141&cpt=8&wpid=1074" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> heparin-congress Government & Politics,News,Public Health http://player.clipsyndicate.com/view/2455/427998 <table border='0' cellpadding='0' cellspacing='0'><tr valign='top'><td><a href='http://www.clipsyndicate.com/video/playlist/2455/427998/?cpt=8&wpid=1074'><img src='http://video-static.clipsyndicate.com/cs-video/vol2/2007/10/24/58/351/5071c2c1-a0e0-43ad-8de7-9bd486553291_120x90.jpg' border='0' /></a></td><td style='padding:5px;'>Warner-Lambert vs. Kent - Analysis and Discussion with Mark Herrmann of Jones Day; Laws in Eight States Currently Shield Pharma From Product Liability Claims</td></tr></table> http://www.clipsyndicate.com/video/playlist/2455/427998/?cpt=8&wpid=1074 Wed, 24 Oct 2007 17:45:00 +0000 In-Depth Look: Big Pharma & Supreme Court Warner-Lambert vs. Kent - Analysis and Discussion with Mark Herrmann of Jones Day; Laws in Eight States Currently Shield Pharma From Product Liability Claims http://www.clipsyndicate.com/video/playlist/2455/427998/?cpt=8&wpid=1074 Bloomberg-Clip arkets. existing home sales, their biggest fall since 1999. can it get worse? and a day of extremes for merrill lynch hit by losses on sub-prime debt. the biggest quarterly loss in its 93-year history. we will speak to josh rosner and see if more problems are ahead for them. that is coming up starting at 2:00. back to you. >> thank you, kathleen. a big step -- a big case in the supreme court dealing with the fda regulation approval of drugs bars liability lawsuits under state laws against the manufacturers of these products. at stake is that big pharmaceutical can be sued for damages. joining us to talk about it is a traitor. when we talk bout the liability statutes and the concerns about barring liability for these companies, lay it out in layman' s terms. -- trader. what does that mean for pharmaceutical companies? >> people in michigan and texas would not be able to sue drug cases. people in six other states could not be able to recover punitive damages. it is high stakes. >> the case was filed in 2000. what they are deciding is someone -- a plaintiff -- in a state sues a fork -- pharmaceutical or device company over problems they say are from the drugs or the devices, does the fda' s approval of the drug automatically bar lawsuits or liability? >> wh t we have our eight states that say the drug companies are in one way or another immune from lawsuits unless the company defrauded the fda. the question is whether or not that fraud is valid. if not, what is left? just immunity? that would be great for industry, or nothing at all which would be bad for industry. >> how do you think it will shake out? >> i think it is an easy one. the supreme court decided on something similar to this in 2001, and i am confident they will reach the same result. >> which is fda approval is the last line of authority with regard to punitive damages. >> it would mean private plaintiffs cannot sue for fraud. in michigan and texas, most lawsuits would be under state law. in four other states, and punitive damages would not be allowed. >> nless they defrauded the fda, that would be the only exception, correct? >> that is the hard part. how can you prove that. does it take fda itself saying that it was defrauded or can a state jury make that decision. >> there is the wild card because if the case comes down as you think it might, pharmaceuticals may think they won. how many instances will there be of claims of fraud? and what does it take to show -- maybe it is better for an fda regulator -- about what do you have to do to show fraud against fda? >> in every lawsuit, the plaintiffs say the drug company defrauded the fda. if that is allowed to go forward, the planets should say that you should ave submitted more information. the fda itself generally does not think it was defrauded. the question is, who makes that decision? >> it is interesting. if the pharmaceuticals wind, it would not be clear sailing for the companies because they will most often claim fraud against the fda, regardless. >> if they are in favor of industry, -- the way it works is that you have a statute that gives immunity. unless the company defrauded the fda. if the supreme court knocked out the exception, all you have is immunity. what you are left with is you cannot sue the drug company. that is a good result for pharmaceuticals. >> thank you for <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=427998&cpt=8&wpid=1074"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=427998&cpt=8&wpid=1074" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> Healthcare, Local/Regional, Government, Finance News News http://player.clipsyndicate.com/view/2455/422993 <table border='0' cellpadding='0' cellspacing='0'><tr valign='top'><td><a href='http://www.clipsyndicate.com/video/playlist/2455/422993/?cpt=8&wpid=1074'><img src='http://video-static.clipsyndicate.com/cs-video/vol2/2007/10/18/58/351/a7262391-5f03-4edf-a60c-3718720d241d_120x90.jpg' border='0' /></a></td><td style='padding:5px;'>3Q Profit Rose 6%, Led by Cymbalta and Cialis Sales</td></tr></table> http://www.clipsyndicate.com/video/playlist/2455/422993/?cpt=8&wpid=1074 Thu, 18 Oct 2007 12:21:00 +0000 Interview with Eli Lilly President John Lechleiter 3Q Profit Rose 6%, Led by Cymbalta and Cialis Sales http://www.clipsyndicate.com/video/playlist/2455/422993/?cpt=8&wpid=1074 Bloomberg-Clip actoring in a $1.3 billion write-down for its phone unit, they posted their first loss since going public nine years ago. that said, they increased full- year profit as well as sales forecast. also, eli lilly up this morning with earnings coming in ahead of what analysts were looking for. their stock is up 9% this year. to take a closer look, the president at eli lilly and he joins us from indianapolis. >> good morning. >> what is behind the improved earnings forecast? >> fundamentally, sales growth. we have had solid sales growth this year and in that last half of the year we see an increase in volume. the adjusted sales growth in the third quarter included an 8% contribution from volume growth. that s the best since 2001. >> i wanna talk about products but also want to talk about what is in development. analysts say earnings are not as important as the advanced studies on your anti-clotting drug and a new diabetes drug. you' re anti-clotting drug, when are you anticipating that you will release this? >> we have not -- speculated on the launch, but the next event will be initial data results which will be presented by a group of investigators who have been studying our drug against its competitors. that will come on november 4 as part of the american heart association meeting. >> what would be your ideal time line from there? >> we would be filing by the end of the year after the release of the data, if it is positive. of course, there is a review cycle from the fda that typically takes 12-18 months. >> what about the improved version of the diabetes drug? >> it would only be a once a week preparation of our current product which is administered twice a day. those results will come out later this year. we have not given an exact date of the filing. we need to complete clinical trials and get them manufacturing plant started up. >> you also announced a deal with macrogenics. how does hat fit into your pipeline? >> it gives us a technology platform. what we licensed in is a humanized antibody. when you have type 1 diabetes, where we believe this drug could be affected, your own amine system is essentially killing some cells in your pancreas that produce insulin. we believe this antibody will interfere with the process and reduce those t-sells -- cells. hopefully it will slow the development of diabetes. >> we also want to talk about cost. the head of the company quoted in a release this morning, talking up containing costs. t has been an important issue for pharmaceutical companies. what can you give us in terms of indications? what are you targeting in terms of cost containment or in terms of dollar amount? >> we have been looking at cost across the board for several years and we are clear that we intend to grow operating expenses at a slower rate than sales. this is a multi-pronged approach. we reduced our head count the last three years by about 5000 people, mainly through managing attrition. we are controlling manufacturing expenses well. we are also using a big productivity program to improve performance across the board. >> with a drug company, there are so many factors given insurance. you talk about being held by the weak dollar. lso, selling prices. given the economic environment, how does a slowdown affect what you see in terms of revenue growth and that sells off-price that you are talking about? >> selling prices are a function of many things, including a discount that we negotiate with the people who ultimately provide our products and pay for our products. we are pleased that most of our growth this quarter has come from volume. we expect a price environment in the next few years not terribly different from what we saw earlier in the decade. there are a lot of factors both in the u.s. and internationally that are pushing down on price. >> we have to leave it there, thanks for going us. have a good day. -- joining us. finally, sony is <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=422993&cpt=8&wpid=1074"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=422993&cpt=8&wpid=1074" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> Healthcare, Finance News, Public Companies, International, Local/Regional News http://player.clipsyndicate.com/view/2455/422886 <table border='0' cellpadding='0' cellspacing='0'><tr valign='top'><td><a href='http://www.clipsyndicate.com/video/playlist/2455/422886/?cpt=8&wpid=1074'><img src='http://video-static.clipsyndicate.com/cs-video/vol2/2007/10/18/58/351/522844c3-0f3b-40ae-809e-63fab3ccc6c3' border='0' /></a></td><td style='padding:5px;'>Comments from Holger Geissler, DWS</td></tr></table> http://www.clipsyndicate.com/video/playlist/2455/422886/?cpt=8&wpid=1074 Thu, 18 Oct 2007 07:33:00 +0000 Outlook on Novartis and pharmaceutical stocks Comments from Holger Geissler, DWS http://www.clipsyndicate.com/video/playlist/2455/422886/?cpt=8&wpid=1074 Bloomberg-Clip <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=422886&cpt=8&wpid=1074"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=422886&cpt=8&wpid=1074" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> News http://player.clipsyndicate.com/view/2455/390822 <table border='0' cellpadding='0' cellspacing='0'><tr valign='top'><td><a href='http://www.clipsyndicate.com/video/playlist/2455/390822/?cpt=8&wpid=1074'><img src='http://video-static.clipsyndicate.com/cs-video/86/379/d4de7871-382f-421c-bf9e-e35d4f1a1c69_120x90.jpg' border='0' /></a></td><td style='padding:5px;'>In new study, doctors examined serious side effects from prescription drugs reported to the FDA.</td></tr></table> http://www.clipsyndicate.com/video/playlist/2455/390822/?cpt=8&wpid=1074 Tue, 11 Sep 2007 03:00:00 +0000 Fatal Side Effects In new study, doctors examined serious side effects from prescription drugs reported to the FDA. http://www.clipsyndicate.com/video/playlist/2455/390822/?cpt=8&wpid=1074 WLOS ABC Greenville from the north carolina education lottery. make a minimum $5 purchase on a single carolina cash 5 ticket, and receive a mail-in entry form at the time of purchase for the chance to win one of five new ford mustangs. five new, loaded ford mustangs will be awarded, one per week for five weeks. promotion starts september 10. final drawing, october 31. see nc-educationlottery.org or your retailer for details. medications don't work in the ways we expect them to, the side effects can be serious...the outcome sometimes fatal. now new research is drawing attention to both...as abc's doctor timothy johnson explains in tonight's health headlines. in a new study, doctors examined serious side effects from prescription medications reported to the united states food and drug administration. they found the number of cases has increased dramatically in recent years - rising from nearly 35,000 in 1998 to almost 90,000 in 2005. over 15,000 different drugs were involved, but death was most closely linked to pain medications such as oxycodone and immune system drugs such as remicade. researchers say several factors could be contributing to the increase. one possibility is that doctors are more aware of side effects now and report them more often. in addition, as the population ages, more people need prescription medications, which leaves them at risk for side effects. people are also using multiple drugs at a time - researchers found one quarter of the patients harmed by drugs were taking five medications or more . but experts conclude that the dramatic rise in side effects means that the existing system is not adequately protecting patients and underscores the need for far-reaching policy changes. with this medical minute, i'm doctor timothy johnson. we' ve heard the warnings...year after <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=390822&cpt=8&wpid=1074"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=390822&cpt=8&wpid=1074" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> http://player.clipsyndicate.com/view/2455/354864 <table border='0' cellpadding='0' cellspacing='0'><tr valign='top'><td><a href='http://www.clipsyndicate.com/video/playlist/2455/354864/?cpt=8&wpid=1074'><img src='http://video-static.clipsyndicate.com/cs-video/58/351/473a05d9-0daf-4779-af69-097ec119936e_120x90.jpg' border='0' /></a></td><td style='padding:5px;'>Interview with Roche CEO William Burns</td></tr></table> http://www.clipsyndicate.com/video/playlist/2455/354864/?cpt=8&wpid=1074 Fri, 20 Jul 2007 12:00:00 +0000 Roche Avastin Cancer Drug Wins EU Nod for Lung Cancer Interview with Roche CEO William Burns http://www.clipsyndicate.com/video/playlist/2455/354864/?cpt=8&wpid=1074 Bloomberg-Clip >> rawsh holdings reported first half profits rising 24% with shares having their biggest gain in more than a year. joining us william burns, chief executive officer at the pharmaceutical division at rawsh. let me ask first about those results that you released. you continue to enjoy strong growth thanks to the best-selling cancer medicines you have such as herceptin but there are signs that competition is catching up. what do you say to that? >> the whole landscape in cancer has been fascinating. we have been one of the first along with our majority ownership in genentech in california to profile new medicines which actually are recollection spanning broadly into the space. it's going to be a rather high hurdle for competition to establish themselves and come in. i have no doubt some people will try, but there's a lot of mileage to go in avastin and the vari us cancer drugs that we sell. >> we have a story coming out this morning that avastin has been approved in europe for fighting an advantaged advantage an advanced stage of lung cancer. >> this is europe in catchup in this indication. it's been here in the states since last fall with genentech. it has now been approved by the europeans. what we also have in europe this may, we started with breast cancer, so avastin has been demonstrated to offer a survival benefit in four cancer types. this is ahead of any of the competition. >> you mentioned herceptin, baste cancer treatment. some analysts suggest you could be close to market saturation with this drug as well. a common concern that analysts have with large drug companies, what do you do develop new drugs? >> most physicians want to start it at a late stage in the disease. that's usually the first registration. then ultimately you get to earlier stages in the cancer and hopefully ultimately to what's called the adjuven setting, so once the cancer has been surgically removed to try to prevent the cancer from coming back and there is concern whether it can further benefit ladies with breast cancer. is this a one-horse drug company? is cancer your main reliance? there is concern that drug companies aren't developing band new treatments for other diseases, just relying on improvements to the ones that they have. >> for rosch, we are making a major impact into the treatment of hepatitis where the majority wner of the product that is 60% of market share here in the united states and around the world, we have some very interesting products coming through in roim rheumatoid arthritis. one of the products in the early stages now and has been used in late stage rheumatoid arthritis. we're studying it earlier, and we have a brand new mechanism which is in our drug, with three out of the four pivotal studies that we will need to satisfy the f.d.a. and european authorities, and those results are coming in impeccably and we will be submitting by the end of this year. whether it's transplantation, virology, or tamiflu, for example, we have helped many world governments get to a stage of preparedness for the pandemic. we do believe we have more work to do in the states. the most recent announcement from the government showed that they're still not fully up to the targets of preparedness they wanted to be. one thing coming out of u courts, amgen's suit against rausch over its anemia drug has to go to trial. is this a big setback for you? >> no, this is as predicted and as amgen has signaled. we are not a patent breaking organization. we have our patd ents published in the united states and we look forward to a judgment in boston in the fall adjudicating our rights. >> bill burns, chief executive officer of the farm suited cals division at rausch. when we come back, we will have the latest world and national news and starbucks an hershey's making a sweet deal together. we'll be back in two minutes. >> <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=354864&cpt=8&wpid=1074"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=354864&cpt=8&wpid=1074" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> News http://player.clipsyndicate.com/view/2455/353490 <table border='0' cellpadding='0' cellspacing='0'><tr valign='top'><td><a href='http://www.clipsyndicate.com/video/playlist/2455/353490/?cpt=8&wpid=1074'><img src='http://video-static.clipsyndicate.com/cs-video/58/351/6deb65fc-5527-4f95-b133-a53074eb3418_120x90.jpg' border='0' /></a></td><td style='padding:5px;'>2Q Results - EPS Down 16% to $0.42, Failing to Meet Estimates of $0.50</td></tr></table> http://www.clipsyndicate.com/video/playlist/2455/353490/?cpt=8&wpid=1074 Wed, 18 Jul 2007 16:00:00 +0000 Stock to Watch: A Double Miss for Pfizer 2Q Results - EPS Down 16% to $0.42, Failing to Meet Estimates of $0.50 http://www.clipsyndicate.com/video/playlist/2455/353490/?cpt=8&wpid=1074 Bloomberg-Clip n, storms are a way at present, but more activity tonight. in the east, spotty activity. the heavy rain is moving off eastern england and long island at the time. seattle and portland, showers associated with a cold front. atlanta, 89, it will get to the mid and upper 90s across the mid-atlantic ahead of the cold front. heavy thunderstorms in the ohio valley. temperatures from nashville to the mid-atlantic states looking at mid nineties. now back to you. >> disappointment is the word some analysts and investors are using to characterize the second quarter results of pfizer. matt nesto joins -- it may not be the biggest drug company any longer. >> they are still ahead by sales, which is typically as we measure it. the stock is down about 4 percent, give or ake a four month low. pfizer, disappointment. analysts, clearly investors are saying that. even the company has the word discipline is their own press release -- were disappointed in their own press release. j.p. morgan referred to it as limping along. clearly not a lot of happiness as the results came out. as well as of the pfizer deal 9 forecast for this year and next, exactly where they are already priced in. 16% decline from a year ago gets you to 42 cents a share. the sales globally were down 6%, 11 billion. but also missed a 11.4 billion, the average estimate you can see the decline there. take a look at the real culprit, lipitor sales in the u.s. were down 5%. that is their best selling drug. it does give or take a building dollars a month in revenues. outside the u.s., lipitor sales were up 5%, but the total haul with the decline in the u.s. saw its 13% klein, but behold, a 25% decline really points up the errors. with the sales and the competition and uncertainty as to how they will adapt to the changing health-care marketplace, they pointed out the cost cuts are not there, and the costs remain high, and that, combined with a disappointment number in celebrant and hit some of their top-selling drug addict to the 4% decline -- celebrex. >> thank you very much. as we reported, fed chairman ben bernanke has been on capitol hill today, for a <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=353490&cpt=8&wpid=1074"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=353490&cpt=8&wpid=1074" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> News http://player.clipsyndicate.com/view/2455/352839 <table border='0' cellpadding='0' cellspacing='0'><tr valign='top'><td><a href='http://www.clipsyndicate.com/video/playlist/2455/352839/?cpt=8&wpid=1074'><img src='http://video-static.clipsyndicate.com/cs-video/4/3/7b8c0fef-ec3c-4a19-9974-d34d85f1298e_120x90.jpg' border='0' /></a></td><td style='padding:5px;'>A Food and Drug Administration plan to close half its laboratories is an assault on food safety that probably would expose more Americans to harm from unsafe food, lawmakers charged Tuesday. (July 17)</td></tr></table> http://www.clipsyndicate.com/video/playlist/2455/352839/?cpt=8&wpid=1074 Tue, 17 Jul 2007 17:06:06 +0000 Congress: FDA Closure Plan Risky for Consumers A Food and Drug Administration plan to close half its laboratories is an assault on food safety that probably would expose more Americans to harm from unsafe food, lawmakers charged Tuesday. (July 17) http://www.clipsyndicate.com/video/playlist/2455/352839/?cpt=8&wpid=1074 Associated Press <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=352839&cpt=8&wpid=1074"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=352839&cpt=8&wpid=1074" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> food-safety International,Science & Technology http://player.clipsyndicate.com/view/2455/352839 <table border='0' cellpadding='0' cellspacing='0'><tr valign='top'><td><a href='http://www.clipsyndicate.com/video/playlist/2455/352839/?cpt=8&wpid=1074'><img src='http://video-static.clipsyndicate.com/cs-video/4/3/7b8c0fef-ec3c-4a19-9974-d34d85f1298e_120x90.jpg' border='0' /></a></td><td style='padding:5px;'>A Food and Drug Administration plan to close half its laboratories is an assault on food safety that probably would expose more Americans to harm from unsafe food, lawmakers charged Tuesday. (July 17)</td></tr></table> http://www.clipsyndicate.com/video/playlist/2455/352839/?cpt=8&wpid=1074 Tue, 17 Jul 2007 17:06:06 +0000 Congress: FDA Closure Plan Risky for Consumers A Food and Drug Administration plan to close half its laboratories is an assault on food safety that probably would expose more Americans to harm from unsafe food, lawmakers charged Tuesday. (July 17) http://www.clipsyndicate.com/video/playlist/2455/352839/?cpt=8&wpid=1074 Associated Press <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=352839&cpt=8&wpid=1074"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=352839&cpt=8&wpid=1074" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> food-safety International,Science & Technology http://player.clipsyndicate.com/view/2455/347270 <table border='0' cellpadding='0' cellspacing='0'><tr valign='top'><td><a href='http://www.clipsyndicate.com/video/playlist/2455/347270/?cpt=8&wpid=1074'><img src='http://video-static.clipsyndicate.com/cs-video/58/351/c5aa46aa-de4e-4cca-9147-41e5daf59532_120x90.jpg' border='0' /></a></td><td style='padding:5px;'>Tolevamer Aimed to Treat Sever Diarrhea, No Better Than Antibiotic; Also, Hylastan No Better Than Steroids, and Mixed Results for Renvela</td></tr></table> http://www.clipsyndicate.com/video/playlist/2455/347270/?cpt=8&wpid=1074 Fri, 06 Jul 2007 16:00:00 +0000 Genzyme's Second Disappointment in One Week Tolevamer Aimed to Treat Sever Diarrhea, No Better Than Antibiotic; Also, Hylastan No Better Than Steroids, and Mixed Results for Renvela http://www.clipsyndicate.com/video/playlist/2455/347270/?cpt=8&wpid=1074 Bloomberg-Clip losing its merchant-banking unit. both changes are viewed as a positive. clearly investors are saying the same thing. gold stocks are all on the move. >> while markets on hold are higher, genzyme is the biggest drag on the nasdaq. let' s get an update at the nasdaq. >> one of the world' s largest biotech companies, just as a point of reference, its experimental drug is a treatment for diarrhea and it says is no better than a standard antibiotic. that sent the company' s shares down. his first of two preclinical trials say the drug was no more effective than the standard antibiotic. the results represent a blow to genzyme as it had been considered a e to have a promising drug. these are disappointing results but the potential for commercializing the drug, that is what the ceo of g genzyme said. the condition is caused by a type of back. and can -- type of a back. -- bacteria. this is also the second time that genzyme has reported disappointing clinical trial results. on thursday, it said one of its experimental treatments for pain associated with osteoarthritis was no better than a standard steroid. ellis was to be a single injection in treatment. -- that was supposed to be a single injection treatment. they say today' s half results will result in further scrutiny. jpmorgan says they are retaining a neutral rating on the stock. hey had not considered this on the stocks. >> we' re also in the middle of the longest winning streak for crude oil futures in a year. there any -$73. what' s more at that. nigeria is certainly unfocused but it is not all but the continued problems in the country for oil. >> that is the head scratcher for many oil investors who would point out yesterday' inventory reports show bearish fills across the board. they ended up in oil moving higher once again. when you get what traders call bullish action in the face of bearish news, they say it is the most bullish signal out there. let' s look at the seven-eight charts. it is a bold dream. seven days high, we began the run at 67.83. that is a $5 gain. take a look at brent oil, which is traded out of london <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=347270&cpt=8&wpid=1074"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=347270&cpt=8&wpid=1074" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> News http://player.clipsyndicate.com/view/2455/335398 <table border='0' cellpadding='0' cellspacing='0'><tr valign='top'><td><a href='http://www.clipsyndicate.com/video/playlist/2455/335398/?cpt=8&wpid=1074'><img src='http://video-static.clipsyndicate.com/cs-video/58/351/4d2b6b7e-cba7-4c49-b214-995a0d216b97_120x90.jpg' border='0' /></a></td><td style='padding:5px;'>Interview with Gov. Anibal Acevedo Vila of the Commonwealth of Puerto Rico; Puerto Rico Has 10% Unemployment Rate; Budget Shortfall</td></tr></table> http://www.clipsyndicate.com/video/playlist/2455/335398/?cpt=8&wpid=1074 Fri, 08 Jun 2007 18:00:00 +0000 Pharma Focus: Promoting Puerto Rico Interview with Gov. Anibal Acevedo Vila of the Commonwealth of Puerto Rico; Puerto Rico Has 10% Unemployment Rate; Budget Shortfall http://www.clipsyndicate.com/video/playlist/2455/335398/?cpt=8&wpid=1074 Bloomberg-Clip >> a quick trivia question. where are two-thirds of the trout drugs sold in the united states produced? many are building offshore operations but technically in meeting the safety of the united states. the answer is border rico. there governor, anibal acevedo- vila is in the new york today. i asked him how important the biotech industry has become to them. >> manufacturing accounts for 40% of our gdp. those are the most important sectors. we have been a manufacturing powerhouse of pharmaceutical products for many years, and now we are quickly becoming a powerhouse of biological health. we have landed deals with amgen, eli lilly, other organizations. we are looking for more, and he results are very impressive. >> as governor, you have made support for the biotech industry a public priority. you called in the bio island. why? >> we have been so successful in producing the products. we have the elements in terms of experience from pharmaceutical companies. we have the professionals needed, the engineers, ph.d. in science. we have access to the u.s. market. and as you mentioned, we are outside of the u.s. for tax purposes, but part of the commonwealth for other protections that companies need. in terms of biotech for example, five years ago we only had one operation. now, four years after, 25 percent of all the world output of biologic omes from pr. we are ready for more and that is why i am here in new york, to attract more investment to the island because the stories are very successful. in that sense, it is a combination of good business claims and tax incentives and a high quality of labor that we have in pr. >> talk to me about the larger economy, despite progress and attracting by attack, you are facing a recessionary time. you have a 10% unemployment rate. >> in terms of the unemployment, i agree it is high. it has been a problem for the last 20 years. precisely, to jump-start the economy and move to a new economy, the new public policy is to move pr to a more knowledge based economy, to not only o into the manufacturing of biotech products, but research and development. we are investing in education, science and math. the presence of big pharmaceutical companies on the island has a strong relationship with the people in my support will get that new investment needed to move for rico' economy forward. i agree that is a main issue. we are very much committed to attract new commitments and foster investment and development of small companies from pr. >> what about the fiscal issues? there was a government shutdown last year. you are looking at a budget shortfall this year, will you be able to balance that have beset by the next fiscal year? >> for the fourth consecutive year we will be spending less money. the first time in history when we have irst -- real fiscal responsibility. the budget i announced is smaller than the current budget and expenses. in that sense, we are solving fiscal problems. we have a plan that is moving forward. there is no threat of a government shutdown. the end of the fiscal year is on june 3. that was one of the big problems i inherited. we are solving that problem. we are ready in june or july to have a $1.5 billion bond issue of government sponsored bonds. another $5 billion bond issue will probably happen in july or august. i think the markets are going to welcome pr and isn' t -- the decisions we have made are put through the house. that is another good reason why i am confident and optimistic that our economy will move forward. y thanks to the government of the commonwealth of pr, anibal acevedo-vila. also, he will be throwing in on every pitch at a baseball game. world and national news coming up next, and an update from su keenan on oil. <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=335398&cpt=8&wpid=1074"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=335398&cpt=8&wpid=1074" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> News http://player.clipsyndicate.com/view/2455/343723 <table border='0' cellpadding='0' cellspacing='0'><tr valign='top'><td><a href='http://www.clipsyndicate.com/video/playlist/2455/343723/?cpt=8&wpid=1074'><img src='http://video-static.clipsyndicate.com/cs-video/58/351/b296eedb-aab9-4b82-a550-8e4c5e77627a_120x90.jpg' border='0' /></a></td><td style='padding:5px;'>Analysis and Discussion with Eric Dezenhall of Dezenhall Resources, Author of "Damage Control": Attack the Message, Not the Messenger; Crisis Communications</td></tr></table> http://www.clipsyndicate.com/video/playlist/2455/343723/?cpt=8&wpid=1074 Wed, 27 Jun 2007 21:00:00 +0000 How Should the Healthcare Industry React to Michael Moore's Film? Analysis and Discussion with Eric Dezenhall of Dezenhall Resources, Author of "Damage Control": Attack the Message, Not the Messenger; Crisis Communications http://www.clipsyndicate.com/video/playlist/2455/343723/?cpt=8&wpid=1074 Bloomberg-Clip charlotte, north carolina. here in washington, and health care -- and across the country, the health-care industry is getting ready for a new movie from michael moore. it deals with the health-care industry, it is called roy blunt -- it is called "sicko" we spoke to a crisis management consultant, we got his take on exactly how the industry should respond. >> michael moore has taken on the automobile industry, the gun lobby, and president bush, his latest film takes aim at the health-care industry. here is a sneak peek at the film. >> i had a piece of wood, i grabbed it. >> he saw the top -- sawed off the top of two of his fingers. >> i did not have ins rance. >> the hospital gave him a choice, reattached the middle finger for $50,000, or the ring finger could be reattached for $12,000. >> he wanted -- it wanted him to put a value on his body. >> he chose the ring finger, for the bargain price of $12,000. >> the drug and insurance companies are reacting to the film' s release in a statement earlier this month. the manufacturers of america said that they could find ways to improve america' s health-care system. but the one-sided attack would not help the cause. what will this film did to the industry? we have the ceo of technological resources, he is the author of a famous book, "everything you know about crisis management is wrong." he wants to talk about the health-care industry, and whether or not they s ould be worried. >> they should be worried. they' re in a battle with conventional forces in the health-care industry. he has a great story, and the industry is simply not equipped to respond to a guerrilla fighter will there -- to a guerrilla fighter. will there be a response? they have to do what they do not have to do, which is fighting a guerrilla war. >> will be the advice that you would give them? >> do not attack him personally. attack the message. he wants you to attack him personally. he wants it to look like it is a dirty trick. but what third parties to attack him and his credibility. secondly, there are opportunities to be able to explain this. ell the different stories of people who did not do well in cuba. places where the people have seen better recovery. tell the alternatives to the other stories. that is far better. it is better than individual companies going after him. there is nothing to gain by this personally. >> he had previous films, he has a long list here. they' re taking aim at specific targets. >> the goal of the industry is to lose by fighting less. the way that you do this is that you do not debate him by keeping this going longer than it would otherwise. you have to have very simple characterization' s that take it out of the news faster than it would if you engage in world war three. if you declare war on him, there is a chance that he will in. the industry is very conservative and needs to be so in their response. >> last week, there was an advertisement, it was an invitation with 1000 names in it to the lobbyists of the health- care industry. all the names were in the advertisement. i am not sure if anyone showed up. it may drop even more attention to this film. >> that is his real genius -- draw even more attention to this film. >> that is his real genius. he is a bomb thrower, never fight him. it is a clever tactic to get health care industry professionals involved. >> why not go after him personally? there are questions about whether he is truthful, ut not call him on this? >> people can, but it should not be health care companies. why would you want to inject yourself into this? have think tanks and like-minded parties involved. if i were counseling the individual company, and i have seen this done, i do not see why the drug companies gain by fighting him. this is my job. >> thank you very much for your time. michael moore' s new film, "sicko" and how the industry may respond. and the end of an era in britain, we will talk about tony blair' s final days. <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=343723&cpt=8&wpid=1074"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=343723&cpt=8&wpid=1074" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> News http://player.clipsyndicate.com/view/2455/340439 <table border='0' cellpadding='0' cellspacing='0'><tr valign='top'><td><a href='http://www.clipsyndicate.com/video/playlist/2455/340439/?cpt=8&wpid=1074'><img src='http://video-static.clipsyndicate.com/cs-video/58/351/a0d09e10-18da-43c9-86c3-def64213ab3f_120x90.jpg' border='0' /></a></td><td style='padding:5px;'>Bristol-Meyers's Plavix is World's Third-Best Selling Drug; Potential Suitors - Sanovi-Aventis, Pfizer, AstraZeneca, GlaxoSmithKline; Plavix Court Decision Lowers Uncertainly; UBS Sees Takeout Prospects Up to $37/share; Bristol Meyers Declines to Comment on Takeover Talk</td></tr></table> http://www.clipsyndicate.com/video/playlist/2455/340439/?cpt=8&wpid=1074 Wed, 20 Jun 2007 13:00:00 +0000 Bristol-Meyers Squibb: A Takeover Target Again? Bristol-Meyers's Plavix is World's Third-Best Selling Drug; Potential Suitors - Sanovi-Aventis, Pfizer, AstraZeneca, GlaxoSmithKline; Plavix Court Decision Lowers Uncertainly; UBS Sees Takeout Prospects Up to $37/share; Bristol Meyers Declines to Comment on Takeover Talk http://www.clipsyndicate.com/video/playlist/2455/340439/?cpt=8&wpid=1074 Bloomberg-Clip >> i just want to point out what is happening in the stock market, where stocks have erased the early gains. the s&p came within two of the record close but has retreated. exon, j.p. morgan, pfizer will be the biggest drags on the s&p -- exxon mobil. bristol-myers -- there is speculation it could be a takeover target again. the latest speculation comes after the court victory on plavix reassured potential suitors. we will have a closer look with shannon the covering the drug stock. this speculation and it seemed is around every few months when it comes to this particular drug company. why is it such an attractive target, and why now? >> basically a lot of the world' s drug companies need new products. they are facing a generic competition and they have had some major research setbacks. bristol-myers had some of the best pipelines in the drug industry, analysts say, especially on a oncology. that is why they are looking at it now. with the plavix decision, it puts a lot of risk behind them, and bristol-myers is one of the most attractive. >> with plavix being the top seller and staving off generic drugs stable cash flow is anticipated for sales. there is a lot of analyst -- are a lot of analysts otes, a lot of names banded about. >> sanofi is a top mentioned, they are a partner with bristol- myers on plavix. also sanofi had a setback if you weeks ago where they had a weight loss drug that it wanted to market, and a panel of fda advisers recommended against it. it does not look like it is likely that it will make it to market in the u.s.. so they are even in more need for new drugs. pfizer will lose $21 billion in annual revenue by 2011 from generic competition. they are nothing nearer replacing that in development. so, they need new drugs, and fast. and bennett glaxosmithkline has been mentioned. they had some -- and then at glaxosmithkline has been mentioned, they had a heart concerned w one of their new drugs. >> have you heard that talks are going on? have the company -- has the company said it would be open to negotiation? >> there have been sources that said certain companies have hired investment bankers. pfizer said it everything is on the table. but pfizer has gotten burned by mega mergers in the past but did not turn out the way it hoped. a lot of analysts say that pfizer may not have the stomach for a big merger again. >> what about any kind of potential premium? again, in the context that bristol-myers has been a speculative target for so long. how much is already priced in the? >> it looks like analysts say between $35, up took $40 -- it is trading at about $32 today. it is a better premium they talking about before the plavix deal yesterday. >> in terms of who is not on the list of potential acquirers, and one that pops up as interesting? >> the one interesting -- if there is a dark horse, it could be schering-plough. they just did a big deal, so maybe they are out of it. but their ceo had been in the running to be the bristol-myers ceo. it was rumored that he said, yes, i will be your ceo if you take my company and maybe at times -- at a time bristol- myers was not ready for that. >> we are seeing the shares down 0.25 percent right now but they were up yesterday just over four percent. shannon, thanks so much. i just want to point out in terms of stocks, you are little changed -- wait -- yes, little changed. <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=340439&cpt=8&wpid=1074"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&va_id=340439&cpt=8&wpid=1074" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> News